The importance of the B cell component in the evolution from at-risk individuals to RA has also been demonstrated in the PRAIRI study, a clinical trial in ACPA-positive at-risk individuals, in which B cell depletion through a single dose of rituximab significantly delayed disease onset compared to placebo (173). This evidence concerns the gene PRTN3 and rheumatoid arthritis.